【Description】
The global market for Insulin Detemir was estimated to be worth US$ 5586 million in 2025 and is projected to reach US$ 2630 million, growing at a CAGR of -10.2% from 2026 to 2032.
The potential shifts in the 2025 U.S. tariff framework pose substantial volatility risks to global markets. This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Insulin Detemir cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.
洗剤インシュリン―グローバル市場シェアとランキング、全体の売上と需要予測、2026~2032
Key Market Statistics
Pre-Measurement Period
2025Year~2032Year
2025Year Evaluation
5586US$ M
2026Year Evaluation
5016US$ M
2032Year Evaluation
2630US$ M
CAGR(2025~2032)Year
-10.2%
Insulin Detemir is a long-acting basal insulin analog and a soluble biologic medicine manufactured through recombinant DNA expression in Saccharomyces cerevisiae followed by chemical modification. Compared with human insulin, the threonine residue at position B30 is removed and a C14 myristic fatty-acid side chain is attached to lysine at position B29. This molecular design allows the product to remain soluble after subcutaneous injection while prolonging action through self-association and reversible albumin binding, thereby slowing absorption and extending systemic exposure. Commercial formulations are typically clear, colorless, aqueous injections at 100 units/mL, commonly supplied as 3 mL cartridges or pre-filled pens containing 300 units each, with excipients such as glycerol, phenol, metacresol, zinc acetate, disodium phosphate dihydrate, sodium chloride, and water for injections. The product belongs to the basal insulin/long-acting insulin analog category and is mainly used for background glycemic control in type 1 and type 2 diabetes, either alone or in combination with prandial insulin, oral antidiabetic agents, or GLP-1 receptor agonists. Industrial production requires strong capabilities in recombinant expression and purification, structural modification consistency, sterile fill-finish, cold-chain handling, delivery-device compatibility, potency and impurity control, as well as pharmaceutical and clinical comparability evaluation. Manufacturers capable of supplying this product are typically large biologics companies or specialist insulin producers with established industrial know-how.
The global diabetes patient base continues to expand. The 2025 IDF figures indicate about 589 million adults aged 20-79 living with diabetes worldwide, with a projection of 853 million by 2050, while WHO continues to describe diabetes as a major global health burden. Against this backdrop, basal insulin remains a core therapy category for type 1 diabetes and for part of the type 2 diabetes population, so total basal-insulin demand is not shrinking. For Insulin Detemir specifically, however, the practical opportunity is no longer large-scale new patient penetration, but rather stable switching of existing patients, localized supply continuity, hospital and retail substitution management, and refined service in markets where registrations and inventories still remain. For companies with biologics process capability, sterile fill-finish, cold-chain infrastructure, and device-integration experience, Insulin Detemir may still retain short-term value in regulatory, supply, and transition-management settings.
From a medium- to long-term perspective, the constraints on Insulin Detemir are stronger than the opportunities. Novo Nordisk has confirmed the permanent withdrawal of Levemir in the United States, EMA has confirmed that the affected EU presentations will be discontinued before the end of 2026, and UK communications also state that no new patients should be started. Public company websites, regulatory databases, and official product information do not show an established follow-on marketed biosimilar landscape for Insulin Detemir in major regulated markets, meaning supply is highly concentrated in a single operating subject. As a result, market size, manufacturing continuity, regulatory maintenance, and commercial access are all strongly influenced by one company’s portfolio decisions. At the same time, clinical and commercial focus in basal insulin is continuing to move toward insulin glargine, insulin degludec, and longer-duration products, leaving Insulin Detemir at a disadvantage in prescribing priority, dosing frequency, channel economics, and resource allocation.
Downstream demand is shifting from “new patient initiation” to “existing patient maintenance and therapeutic switching.” Hospitals are likely to place greater weight on supply continuity, reimbursement access, hypoglycemia management, dosing convenience, and training burden, which favors basal insulins with more stable supply and longer lifecycle visibility. Retail and community channels are more focused on post-switch glucose variability, body-weight effects, learning costs for delivery devices, and prescription refill convenience. Short-term residual demand will remain among pediatric patients, pregnancy-related use, and people highly attached to specific brands or devices, but over 2026-2032 the real downstream pattern for Insulin Detemir is more likely to be inventory depletion, structural substitution, and regimen migration rather than independent and sustainable market expansion.
This report provides a comprehensive view of the global market for Insulin Detemir, covering total sales volume, sales revenue, pricing, the market share and ranking of key companies, along with analyses by region & country, by Type, and by Application.
The Insulin Detemir market size, estimations, and forecasts are presented in terms of sales volume (千本) and revenue ($ millions), with 2025 as the base year and historical and forecast data from 2021 to 2032. The report combines quantitative and qualitative analysis to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current marketplace, and make informed business decisions regarding Insulin Detemir.
Market Segmentation
Chapter Outline
Chapter 1: Introduces the scope of the report and the global market size (value, volume, and price). It also summarizes market dynamics and Recent Developments; identifies key drivers and restraints; outlines challenges and risks for manufacturers; reviews relevant industry policies and U.S. tariff implications.
Chapter 2: Provides a detailed analysis of the Insulin Detemir manufacturers' competitive landscape—including pricing, sales and revenue shares, Recent Developments plans, and mergers and acquisitions (M&A).
Chapter 3: Analyzes market segmentation by Type, presenting the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 4: Analyzes market segmentation by Application, presenting the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 5: Presents Insulin Detemir sales and revenue at the regional level. It offers a quantitative assessment of market size and growth potential by region and summarizes market development, future prospects, addressable space, and country-level market size worldwide.
Chapter 6: Presents Insulin Detemir sales and revenue at the country level. It provides segmented data by Type and by Application for each country/region.
Chapter 7: Profiles key players, detailing the main companies' product sales, revenue, pricing, gross margin, product portfolios, Recent Developments, etc.
Chapter 8: Analyzes the industry value chain, including upstream suppliers and downstream applications/customers.
Chapter 9: Conclusion.
【Table of Contents】
1 Market Overview
1.1 Insulin Detemir Product Introduction
1.2 Global Insulin Detemir Market Size Forecast
1.2.1 Global Insulin Detemir Sales Value (2021–2032)
1.2.2 Global Insulin Detemir Sales Volume (2021–2032)
1.2.3 Global Insulin Detemir Sales Price (2021–2032)
1.3 Insulin Detemir Market Trends & Drivers
1.3.1 Insulin Detemir Industry Trends
1.3.2 Insulin Detemir Market Drivers & Opportunities
1.3.3 Insulin Detemir Market Challenges
1.3.4 Insulin Detemir Market Restraints
1.3.5 Impact of U.S. Tariffs
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Insulin Detemir Players Revenue Ranking (2025)
2.2 Global Insulin Detemir Revenue by Company (2021–2026)
2.3 Global Insulin Detemir Sales Volume Ranking of Players (2025)
2.4 Global Insulin Detemir Sales Volume by Company (2021–2026)
2.5 Global Insulin Detemir Average Price by Company (2021–2026)
2.6 Key Manufacturers Insulin Detemir Manufacturing Base and Headquarters
2.7 Key Manufacturers Insulin Detemir Product Offerings
2.8 Key Manufacturers Start of Mass Production of Insulin Detemir
2.9 Insulin Detemir Market Competitive Analysis
2.9.1 Insulin Detemir Market Concentration Rate (2021–2026)
2.9.2 Global 5 and 10 Largest Manufacturers by Insulin Detemir Revenue in 2025
2.9.3 Global Companies by Tier (Tier 1, Tier 2, Tier 3), based on Insulin Detemir revenue, 2025
2.10 Mergers & Acquisitions and Expansion
3 Segmentation Insulin Detemir Market Classification
3.1 Introduction by Type
3.1.1 Resuable
3.1.2 Disposable
3.1.3 Global Insulin Detemir Sales Value by Type
3.1.3.1 Global Insulin Detemir Sales Value by Type (2021 vs 2025 vs 2032)
3.1.3.2 Global Insulin Detemir Sales Value, by Type (2021–2032)
3.1.3.3 Global Insulin Detemir Sales Value, by Type (%), 2021–2032
3.1.4 Global Insulin Detemir Sales Volume by Type
3.1.4.1 Global Insulin Detemir Sales Volume by Type (2021 vs 2025 vs 2032)
3.1.4.2 Global Insulin Detemir Sales Volume, by Type (2021–2032)
3.1.4.3 Global Insulin Detemir Sales Volume, by Type (%), 2021–2032
3.1.5 Global Insulin Detemir Average Price by Type (2021–2032)
3.2 Introduction by Dosage Presentation
3.2.1 Solution for Injection in Vial
3.2.2 Solution for Injection in Cartridge
3.2.3 Solution for Injection in Pre-filled Pen
3.2.4 Others
3.2.5 Global Insulin Detemir Sales Value by Dosage Presentation
3.2.5.1 Global Insulin Detemir Sales Value by Dosage Presentation (2021 vs 2025 vs 2032)
3.2.5.2 Global Insulin Detemir Sales Value, by Dosage Presentation (2021–2032)
3.2.5.3 Global Insulin Detemir Sales Value, by Dosage Presentation (%), 2021–2032
3.2.6 Global Insulin Detemir Sales Volume by Dosage Presentation
3.2.6.1 Global Insulin Detemir Sales Volume by Dosage Presentation (2021 vs 2025 vs 2032)
3.2.6.2 Global Insulin Detemir Sales Volume, by Dosage Presentation (2021–2032)
3.2.6.3 Global Insulin Detemir Sales Volume, by Dosage Presentation (%), 2021–2032
3.2.7 Global Insulin Detemir Average Price by Dosage Presentation (2021–2032)
3.3 Introduction by Value-chain Delivery Level
3.3.1 Insulin Detemir Drug Substance
3.3.2 Bulk Drug Product Solution
3.3.3 Finished Drug Product
3.3.4 Drug-Device Combination Product
3.3.5 Others
3.3.6 Global Insulin Detemir Sales Value by Value-chain Delivery Level
3.3.6.1 Global Insulin Detemir Sales Value by Value-chain Delivery Level (2021 vs 2025 vs 2032)
3.3.6.2 Global Insulin Detemir Sales Value, by Value-chain Delivery Level (2021–2032)
3.3.6.3 Global Insulin Detemir Sales Value, by Value-chain Delivery Level (%), 2021–2032
3.3.7 Global Insulin Detemir Sales Volume by Value-chain Delivery Level
3.3.7.1 Global Insulin Detemir Sales Volume by Value-chain Delivery Level (2021 vs 2025 vs 2032)
3.3.7.2 Global Insulin Detemir Sales Volume, by Value-chain Delivery Level (2021–2032)
3.3.7.3 Global Insulin Detemir Sales Volume, by Value-chain Delivery Level (%), 2021–2032
3.3.8 Global Insulin Detemir Average Price by Value-chain Delivery Level (2021–2032)
3.4 Introduction by Commercial Pack Configuration
3.4.1 Single-unit Pack
3.4.2 Multi-unit Pack
3.4.3 Pen Pack with Needles
3.4.4 Others
3.4.5 Global Insulin Detemir Sales Value by Commercial Pack Configuration
3.4.5.1 Global Insulin Detemir Sales Value by Commercial Pack Configuration (2021 vs 2025 vs 2032)
3.4.5.2 Global Insulin Detemir Sales Value, by Commercial Pack Configuration (2021–2032)
3.4.5.3 Global Insulin Detemir Sales Value, by Commercial Pack Configuration (%), 2021–2032
3.4.6 Global Insulin Detemir Sales Volume by Commercial Pack Configuration
3.4.6.1 Global Insulin Detemir Sales Volume by Commercial Pack Configuration (2021 vs 2025 vs 2032)
3.4.6.2 Global Insulin Detemir Sales Volume, by Commercial Pack Configuration (2021–2032)
3.4.6.3 Global Insulin Detemir Sales Volume, by Commercial Pack Configuration (%), 2021–2032
3.4.7 Global Insulin Detemir Average Price by Commercial Pack Configuration (2021–2032)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospital
4.1.2 Clinic
4.1.3 Home Use
4.1.4 Others
4.2 Global Insulin Detemir Sales Value by Application
4.2.1 Global Insulin Detemir Sales Value by Application (2021 vs 2025 vs 2032)
4.2.2 Global Insulin Detemir Sales Value, by Application (2021–2032)
4.2.3 Global Insulin Detemir Sales Value, by Application (%), 2021–2032
4.3 Global Insulin Detemir Sales Volume by Application
4.3.1 Global Insulin Detemir Sales Volume by Application (2021 vs 2025 vs 2032)
4.3.2 Global Insulin Detemir Sales Volume, by Application (2021–2032)
4.3.3 Global Insulin Detemir Sales Volume, by Application (%), 2021–2032
4.4 Global Insulin Detemir Average Price by Application (2021–2032)
5 Segmentation by Region
5.1 Global Insulin Detemir Sales Value by Region
5.1.1 Global Insulin Detemir Sales Value by Region: 2021 vs 2025 vs 2032
5.1.2 Global Insulin Detemir Sales Value by Region (2021–2026)
5.1.3 Global Insulin Detemir Sales Value by Region (2027–2032)
5.1.4 Global Insulin Detemir Sales Value by Region (%), 2021–2032
5.2 Global Insulin Detemir Sales Volume by Region
5.2.1 Global Insulin Detemir Sales Volume by Region: 2021 vs 2025 vs 2032
5.2.2 Global Insulin Detemir Sales Volume by Region (2021–2026)
5.2.3 Global Insulin Detemir Sales Volume by Region (2027–2032)
5.2.4 Global Insulin Detemir Sales Volume by Region (%), 2021–2032
5.3 Global Insulin Detemir Average Price by Region (2021–2032)
5.4 North America
5.4.1 North America Insulin Detemir Sales Value, 2021–2032
5.4.2 North America Insulin Detemir Sales Value by Country (%), 2025 vs 2032
5.5 Europe
5.5.1 Europe Insulin Detemir Sales Value, 2021–2032
5.5.2 Europe Insulin Detemir Sales Value by Country (%), 2025 vs 2032
5.6 Asia Pacific
5.6.1 Asia Pacific Insulin Detemir Sales Value, 2021–2032
5.6.2 Asia Pacific Insulin Detemir Sales Value by Region (%), 2025 vs 2032
5.7 South America
5.7.1 South America Insulin Detemir Sales Value, 2021–2032
5.7.2 South America Insulin Detemir Sales Value by Country (%), 2025 vs 2032
5.8 Middle East & Africa
5.8.1 Middle East & Africa Insulin Detemir Sales Value, 2021–2032
5.8.2 Middle East & Africa Insulin Detemir Sales Value by Country (%), 2025 vs 2032
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Insulin Detemir Sales Value Growth Trends, 2021 vs 2025 vs 2032
6.2 Key Countries/Regions Insulin Detemir Sales Value and Sales Volume
6.2.1 Key Countries/Regions Insulin Detemir Sales Value, 2021–2032
6.2.2 Key Countries/Regions Insulin Detemir Sales Volume, 2021–2032
6.3 United States
6.3.1 United States Insulin Detemir Sales Value, 2021–2032
6.3.2 United States Insulin Detemir Sales Value by Type (%), 2025 vs 2032
6.3.3 United States Insulin Detemir Sales Value by Application, 2025 vs 2032
6.4 Europe
6.4.1 Europe Insulin Detemir Sales Value, 2021–2032
6.4.2 Europe Insulin Detemir Sales Value by Type (%), 2025 vs 2032
6.4.3 Europe Insulin Detemir Sales Value by Application, 2025 vs 2032
6.5 China
6.5.1 China Insulin Detemir Sales Value, 2021–2032
6.5.2 China Insulin Detemir Sales Value by Type (%), 2025 vs 2032
6.5.3 China Insulin Detemir Sales Value by Application, 2025 vs 2032
6.6 Japan
6.6.1 Japan Insulin Detemir Sales Value, 2021–2032
6.6.2 Japan Insulin Detemir Sales Value by Type (%), 2025 vs 2032
6.6.3 Japan Insulin Detemir Sales Value by Application, 2025 vs 2032
6.7 South Korea
6.7.1 South Korea Insulin Detemir Sales Value, 2021–2032
6.7.2 South Korea Insulin Detemir Sales Value by Type (%), 2025 vs 2032
6.7.3 South Korea Insulin Detemir Sales Value by Application, 2025 vs 2032
6.8 Southeast Asia
6.8.1 Southeast Asia Insulin Detemir Sales Value, 2021–2032
6.8.2 Southeast Asia Insulin Detemir Sales Value by Type (%), 2025 vs 2032
6.8.3 Southeast Asia Insulin Detemir Sales Value by Application, 2025 vs 2032
6.9 India
6.9.1 India Insulin Detemir Sales Value, 2021–2032
6.9.2 India Insulin Detemir Sales Value by Type (%), 2025 vs 2032
6.9.3 India Insulin Detemir Sales Value by Application, 2025 vs 2032
7 Company Profiles
7.1 Novo Nordisk
7.1.1 Novo Nordisk Company Information
7.1.2 Novo Nordisk Introduction and Business Overview
7.1.3 Novo Nordisk Insulin Detemir Sales, Revenue, Price and Gross Margin (2021–2026)
7.1.4 Novo Nordisk Insulin Detemir Product Offerings
7.1.5 Novo Nordisk Recent Developments
8 Industry Chain Analysis
8.1 Insulin Detemir Industrial Chain
8.2 Insulin Detemir Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Key Suppliers of Raw Materials
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customer Analysis)
8.5 Sales Model and Sales Channelss
8.5.1 Insulin Detemir Sales Model
8.5.2 Sales Channels
8.5.3 Insulin Detemir Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer
【Table of Figures】
List of Tables
Table 1. Insulin Detemir Market Trends
Table 2. Insulin Detemir Market Drivers & Opportunities
Table 3. Insulin Detemir Market Challenges
Table 4. Insulin Detemir Market Restraints
Table 5. Global Insulin Detemir Revenue by Company (US$ Million), 2021–2026
Table 6. Global Insulin Detemir Revenue Market Share by Company (2021–2026)
Table 7. Global Insulin Detemir Sales Volume by Company (K Dose), 2021–2026
Table 8. Global Insulin Detemir Sales Volume Market Share by Company (2021–2026)
Table 9. Global Market Insulin Detemir Price by Company (US$/Dose), 2021–2026
Table 10. Key Manufacturers Insulin Detemir Manufacturing Base and Headquarters
Table 11. Key Manufacturers Insulin Detemir Product Type
Table 12. Key Manufacturers Start of Mass Production of Insulin Detemir
Table 13. Global Insulin Detemir Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Top Manufacturers Market Share by Tier (Tier 1, Tier 2, Tier 3), based on Insulin Detemir revenue, 2025
Table 15. Mergers & Acquisitions and Expansion Plans
Table 16. Global Insulin Detemir Sales Value by Type: 2021 vs 2025 vs 2032 (US$ Million)
Table 17. Global Insulin Detemir Sales Value by Type (US$ Million), 2021–2026
Table 18. Global Insulin Detemir Sales Value by Type (US$ Million), 2027–2032
Table 19. Global Insulin Detemir Sales Market Share in Value by Type (2021–2026)
Table 20. Global Insulin Detemir Sales Market Share in Value by Type (2027–2032)
Table 21. Global Insulin Detemir Sales Volume by Type: 2021 vs 2025 vs 2032 (K Dose)
Table 22. Global Insulin Detemir Sales Volume by Type (K Dose), 2021–2026
Table 23. Global Insulin Detemir Sales Volume by Type (K Dose), 2027–2032
Table 24. Global Insulin Detemir Sales Market Share in Volume by Type (2021–2026)
Table 25. Global Insulin Detemir Sales Market Share in Volume by Type (2027–2032)
Table 26. Global Insulin Detemir Price by Type (US$/Dose), 2021–2026
Table 27. Global Insulin Detemir Price by Type (US$/Dose), 2027–2032
Table 28. Global Insulin Detemir Sales Value by Dosage Presentation: 2021 vs 2025 vs 2032 (US$ Million)
Table 29. Global Insulin Detemir Sales Value by Dosage Presentation (US$ Million), 2021–2026
Table 30. Global Insulin Detemir Sales Value by Dosage Presentation (US$ Million), 2027–2032
Table 31. Global Insulin Detemir Sales Market Share in Value by Dosage Presentation (2021–2026)
Table 32. Global Insulin Detemir Sales Market Share in Value by Dosage Presentation (2027–2032)
Table 33. Global Insulin Detemir Sales Volume by Dosage Presentation: 2021 vs 2025 vs 2032 (K Dose)
Table 34. Global Insulin Detemir Sales Volume by Dosage Presentation (K Dose), 2021–2026
Table 35. Global Insulin Detemir Sales Volume by Dosage Presentation (K Dose), 2027–2032
Table 36. Global Insulin Detemir Sales Market Share in Volume by Dosage Presentation (2021–2026)
Table 37. Global Insulin Detemir Sales Market Share in Volume by Dosage Presentation (2027–2032)
Table 38. Global Insulin Detemir Price by Dosage Presentation (US$/Dose), 2021–2026
Table 39. Global Insulin Detemir Price by Dosage Presentation (US$/Dose), 2027–2032
Table 40. Global Insulin Detemir Sales Value by Value-chain Delivery Level: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Global Insulin Detemir Sales Value by Value-chain Delivery Level (US$ Million), 2021–2026
Table 42. Global Insulin Detemir Sales Value by Value-chain Delivery Level (US$ Million), 2027–2032
Table 43. Global Insulin Detemir Sales Market Share in Value by Value-chain Delivery Level (2021–2026)
Table 44. Global Insulin Detemir Sales Market Share in Value by Value-chain Delivery Level (2027–2032)
Table 45. Global Insulin Detemir Sales Volume by Value-chain Delivery Level: 2021 vs 2025 vs 2032 (K Dose)
Table 46. Global Insulin Detemir Sales Volume by Value-chain Delivery Level (K Dose), 2021–2026
Table 47. Global Insulin Detemir Sales Volume by Value-chain Delivery Level (K Dose), 2027–2032
Table 48. Global Insulin Detemir Sales Market Share in Volume by Value-chain Delivery Level (2021–2026)
Table 49. Global Insulin Detemir Sales Market Share in Volume by Value-chain Delivery Level (2027–2032)
Table 50. Global Insulin Detemir Price by Value-chain Delivery Level (US$/Dose), 2021–2026
Table 51. Global Insulin Detemir Price by Value-chain Delivery Level (US$/Dose), 2027–2032
Table 52. Global Insulin Detemir Sales Value by Commercial Pack Configuration: 2021 vs 2025 vs 2032 (US$ Million)
Table 53. Global Insulin Detemir Sales Value by Commercial Pack Configuration (US$ Million), 2021–2026
Table 54. Global Insulin Detemir Sales Value by Commercial Pack Configuration (US$ Million), 2027–2032
Table 55. Global Insulin Detemir Sales Market Share in Value by Commercial Pack Configuration (2021–2026)
Table 56. Global Insulin Detemir Sales Market Share in Value by Commercial Pack Configuration (2027–2032)
Table 57. Global Insulin Detemir Sales Volume by Commercial Pack Configuration: 2021 vs 2025 vs 2032 (K Dose)
Table 58. Global Insulin Detemir Sales Volume by Commercial Pack Configuration (K Dose), 2021–2026
Table 59. Global Insulin Detemir Sales Volume by Commercial Pack Configuration (K Dose), 2027–2032
Table 60. Global Insulin Detemir Sales Market Share in Volume by Commercial Pack Configuration (2021–2026)
Table 61. Global Insulin Detemir Sales Market Share in Volume by Commercial Pack Configuration (2027–2032)
Table 62. Global Insulin Detemir Price by Commercial Pack Configuration (US$/Dose), 2021–2026
Table 63. Global Insulin Detemir Price by Commercial Pack Configuration (US$/Dose), 2027–2032
Table 64. Global Insulin Detemir Sales Value by Application: 2021 vs 2025 vs 2032 (US$ Million)
Table 65. Global Insulin Detemir Sales Value by Application (US$ Million), 2021–2026
Table 66. Global Insulin Detemir Sales Value by Application (US$ Million), 2027–2032
Table 67. Global Insulin Detemir Sales Market Share in Value by Application (2021–2026)
Table 68. Global Insulin Detemir Sales Market Share in Value by Application (2027–2032)
Table 69. Global Insulin Detemir Sales Volume by Application: 2021 vs 2025 vs 2032 (K Dose)
Table 70. Global Insulin Detemir Sales Volume by Application (K Dose), 2021–2026
Table 71. Global Insulin Detemir Sales Volume by Application (K Dose), 2027–2032
Table 72. Global Insulin Detemir Sales Market Share in Volume by Application (2021–2026)
Table 73. Global Insulin Detemir Sales Market Share in Volume by Application (2027–2032)
Table 74. Global Insulin Detemir Price by Application (US$/Dose), 2021–2026
Table 75. Global Insulin Detemir Price by Application (US$/Dose), 2027–2032
Table 76. Global Insulin Detemir Sales Value by Region, (US$ Million), 2021 vs 2025 vs 2032
Table 77. Global Insulin Detemir Sales Value by Region (US$ Million), 2021–2026
Table 78. Global Insulin Detemir Sales Value by Region (US$ Million), 2027–2032
Table 79. Global Insulin Detemir Sales Value by Region (%), 2021–2026
Table 80. Global Insulin Detemir Sales Value by Region (%), 2027–2032
Table 81. Global Insulin Detemir Sales Volume by Region (K Dose): 2021 vs 2025 vs 2032
Table 82. Global Insulin Detemir Sales Volume by Region (K Dose), 2021–2026
Table 83. Global Insulin Detemir Sales Volume by Region (K Dose), 2027–2032
Table 84. Global Insulin Detemir Sales Volume by Region (%), 2021–2026
Table 85. Global Insulin Detemir Sales Volume by Region (%), 2027–2032
Table 86. Global Insulin Detemir Average Price by Region (US$/Dose), 2021–2026
Table 87. Global Insulin Detemir Average Price by Region (US$/Dose), 2027–2032
Table 88. Key Countries/Regions Insulin Detemir Sales Value Growth Trends, (US$ Million): 2021 vs 2025 vs 2032
Table 89. Key Countries/Regions Insulin Detemir Sales Value, (US$ Million), 2021–2026
Table 90. Key Countries/Regions Insulin Detemir Sales Value, (US$ Million), 2027–2032
Table 91. Key Countries/Regions Insulin Detemir Sales Volume, (K Dose), 2021–2026
Table 92. Key Countries/Regions Insulin Detemir Sales Volume, (K Dose), 2027–2032
Table 93. Novo Nordisk Company Information
Table 94. Novo Nordisk Introduction and Business Overview
Table 95. Novo Nordisk Insulin Detemir Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021–2026)
Table 96. Novo Nordisk Insulin Detemir Product Offerings
Table 97. Novo Nordisk Recent Developments
Table 98. Key Raw Materials Lists
Table 99. Key Suppliers of Raw Materials Lists
Table 100. Insulin Detemir Downstream Customers
Table 101. Insulin Detemir Distributors List
Table 102. Research Programs/Design for This Report
Table 103. Key Data Information from Secondary Sources
Table 104. Key Data Information from Primary Sources
List of Figures
Figure 1. Insulin Detemir Product Picture
Figure 2. Global Insulin Detemir Sales Value, 2021 vs 2025 vs 2032 (US$ Million)
Figure 3. Global Insulin Detemir Sales Value (US$ Million), 2021–2032
Figure 4. Global Insulin Detemir Sales Volume (K Dose), 2021–2032
Figure 5. Global Insulin Detemir Sales Price (US$/Dose), 2021–2032
Figure 6. Insulin Detemir Report Years Considered
Figure 7. Global Insulin Detemir Players Revenue Ranking (US$ Million), 2025
Figure 8. Global Insulin Detemir Sales Volume Ranking of Players (K Dose), 2025
Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Insulin Detemir Revenue in 2025
Figure 10. Insulin Detemir Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 11. Resuable Picture
Figure 12. Disposable Picture
Figure 13. Global Insulin Detemir Sales Value by Type (US$ Million), 2021 vs 2025 vs 2032
Figure 14. Global Insulin Detemir Sales Value Market Share by Type, 2025 & 2032
Figure 15. Global Insulin Detemir Sales Volume by Type (K Dose), 2021 vs 2025 vs 2032
Figure 16. Global Insulin Detemir Sales Volume Market Share by Type, 2025 & 2032
Figure 17. Global Insulin Detemir Price by Type (US$/Dose), 2021–2032
Figure 18. Solution for Injection in Vial Picture
Figure 19. Solution for Injection in Cartridge Picture
Figure 20. Solution for Injection in Pre-filled Pen Picture
Figure 21. Others Picture
Figure 22. Global Insulin Detemir Sales Value by Dosage Presentation (US$ Million), 2021 vs 2025 vs 2032
Figure 23. Global Insulin Detemir Sales Value Market Share by Dosage Presentation, 2025 & 2032
Figure 24. Global Insulin Detemir Sales Volume by Dosage Presentation (K Dose), 2021 vs 2025 vs 2032
Figure 25. Global Insulin Detemir Sales Volume Market Share by Dosage Presentation, 2025 & 2032
Figure 26. Global Insulin Detemir Price by Dosage Presentation (US$/Dose), 2021–2032
Figure 27. Insulin Detemir Drug Substance Picture
Figure 28. Bulk Drug Product Solution Picture
Figure 29. Finished Drug Product Picture
Figure 30. Drug-Device Combination Product Picture
Figure 31. Others Picture
Figure 32. Global Insulin Detemir Sales Value by Value-chain Delivery Level (US$ Million), 2021 vs 2025 vs 2032
Figure 33. Global Insulin Detemir Sales Value Market Share by Value-chain Delivery Level, 2025 & 2032
Figure 34. Global Insulin Detemir Sales Volume by Value-chain Delivery Level (K Dose), 2021 vs 2025 vs 2032
Figure 35. Global Insulin Detemir Sales Volume Market Share by Value-chain Delivery Level, 2025 & 2032
Figure 36. Global Insulin Detemir Price by Value-chain Delivery Level (US$/Dose), 2021–2032
Figure 37. Single-unit Pack Picture
Figure 38. Multi-unit Pack Picture
Figure 39. Pen Pack with Needles Picture
Figure 40. Others Picture
Figure 41. Global Insulin Detemir Sales Value by Commercial Pack Configuration (US$ Million), 2021 vs 2025 vs 2032
Figure 42. Global Insulin Detemir Sales Value Market Share by Commercial Pack Configuration, 2025 & 2032
Figure 43. Global Insulin Detemir Sales Volume by Commercial Pack Configuration (K Dose), 2021 vs 2025 vs 2032
Figure 44. Global Insulin Detemir Sales Volume Market Share by Commercial Pack Configuration, 2025 & 2032
Figure 45. Global Insulin Detemir Price by Commercial Pack Configuration (US$/Dose), 2021–2032
Figure 46. Product Picture of Hospital
Figure 47. Product Picture of Clinic
Figure 48. Product Picture of Home Use
Figure 49. Product Picture of Others
Figure 50. Global Insulin Detemir Sales Value by Application (US$ Million), 2021 vs 2025 vs 2032
Figure 51. Global Insulin Detemir Sales Value Market Share by Application, 2025 & 2032
Figure 52. Global Insulin Detemir Sales Volume by Application (K Dose), 2021 vs 2025 vs 2032
Figure 53. Global Insulin Detemir Sales Volume Market Share by Application, 2025 & 2032
Figure 54. Global Insulin Detemir Price by Application (US$/Dose), 2021–2032
Figure 55. North America Insulin Detemir Sales Value (US$ Million), 2021–2032
Figure 56. North America Insulin Detemir Sales Value by Country (%), 2025 vs 2032
Figure 57. Europe Insulin Detemir Sales Value (US$ Million), 2021–2032
Figure 58. Europe Insulin Detemir Sales Value by Country (%), 2025 vs 2032
Figure 59. Asia Pacific Insulin Detemir Sales Value (US$ Million), 2021–2032
Figure 60. Asia Pacific Insulin Detemir Sales Value by Region (%), 2025 vs 2032
Figure 61. South America Insulin Detemir Sales Value (US$ Million), 2021–2032
Figure 62. South America Insulin Detemir Sales Value by Country (%), 2025 vs 2032
Figure 63. Middle East & Africa Insulin Detemir Sales Value (US$ Million), 2021–2032
Figure 64. Middle East & Africa Insulin Detemir Sales Value by Country (%), 2025 vs 2032
Figure 65. Key Countries/Regions Insulin Detemir Sales Value (%), 2021–2032
Figure 66. Key Countries/Regions Insulin Detemir Sales Volume (%), 2021–2032
Figure 67. United States Insulin Detemir Sales Value (US$ Million), 2021–2032
Figure 68. United States Insulin Detemir Sales Value by Type (%), 2025 vs 2032
Figure 69. United States Insulin Detemir Sales Value by Application (%), 2025 vs 2032
Figure 70. Europe Insulin Detemir Sales Value (US$ Million), 2021–2032
Figure 71. Europe Insulin Detemir Sales Value by Type (%), 2025 vs 2032
Figure 72. Europe Insulin Detemir Sales Value by Application (%), 2025 vs 2032
Figure 73. China Insulin Detemir Sales Value (US$ Million), 2021–2032
Figure 74. China Insulin Detemir Sales Value by Type (%), 2025 vs 2032
Figure 75. China Insulin Detemir Sales Value by Application (%), 2025 vs 2032
Figure 76. Japan Insulin Detemir Sales Value (US$ Million), 2021–2032
Figure 77. Japan Insulin Detemir Sales Value by Type (%), 2025 vs 2032
Figure 78. Japan Insulin Detemir Sales Value by Application (%), 2025 vs 2032
Figure 79. South Korea Insulin Detemir Sales Value (US$ Million), 2021–2032
Figure 80. South Korea Insulin Detemir Sales Value by Type (%), 2025 vs 2032
Figure 81. South Korea Insulin Detemir Sales Value by Application (%), 2025 vs 2032
Figure 82. Southeast Asia Insulin Detemir Sales Value (US$ Million), 2021–2032
Figure 83. Southeast Asia Insulin Detemir Sales Value by Type (%), 2025 vs 2032
Figure 84. Southeast Asia Insulin Detemir Sales Value by Application (%), 2025 vs 2032
Figure 85. India Insulin Detemir Sales Value (US$ Million), 2021–2032
Figure 86. India Insulin Detemir Sales Value by Type (%), 2025 vs 2032
Figure 87. India Insulin Detemir Sales Value by Application (%), 2025 vs 2032
Figure 88. Insulin Detemir Industrial Chain
Figure 89. Insulin Detemir Manufacturing Cost Structure
Figure 90. Channels of Distribution (Direct Sales, and Distribution)
Figure 91. Bottom-up and Top-down Approaches for This Report
Figure 92. Data Triangulation
Figure 93. Key Executives Interviewed